# Definium Therapeutics, Inc.: overview DFTX · Nasdaq · CIK 1813814 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/dftx.md) · [Financials](/companies/dftx/financials.md) · [Filings](/companies/dftx/filings.md) · [Insiders](/companies/dftx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.27)](/filings/0001193125-25-269596.md) | not reported | [(0.35)](/filings/0001193125-26-211989.md) | [(0.50)](/filings/0001193125-26-338066.md) | [(0.78)](/filings/0001193125-25-269596.md) | not reported | [(0.71)](/filings/0001193125-26-211989.md) | [(1.44)](/filings/0001193125-26-338066.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.40)](/filings/0000950170-23-007053.md) | [(1.84)](/filings/0000950170-24-021656.md) | [(2.44)](/filings/0000950170-25-034176.md) | [(1.54)](/filings/0001193125-26-076742.md) | [(2.06)](/filings/0001193125-26-076742.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dftx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $528.4m | 11,232,834 | | Added +2,752,604 | | [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $338.2m | 7,188,888 | | Added +2,188,888 | | [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $322.0m | 6,845,276 | | Added +933,387 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $264.0m | 5,615,645 | | Not compared | | [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $252.5m | 5,367,723 | | New +5,367,723 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $223.6m | 4,752,921 | | Added +2,943,311 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $171.5m | 3,644,813 | | Added +1,149,414 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $144.2m | 3,065,390 | | Added +593,517 | | [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $139.4m | 2,963,410 | | New +2,963,410 | | [Octagon Capital Advisors LP](/funds/1839435.md) | 2026-06-30 | $138.8m | 2,950,000 | | Added +510,000 | ## Recent filings [All 500 filings](/companies/dftx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-14 | 08:02 ET | [8-K](/filings/0001104659-26-107275.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-107275 | | 2026-09-08 | 08:00 ET | [8-K](/filings/0001193125-26-384403.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-384403 | | 2026-08-12 | 08:05 ET | [8-K](/filings/0001104659-26-094528.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-094528 | | 2026-08-06 | 16:16 ET | [10-Q](/filings/0001193125-26-338066.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338066 | | 2026-08-06 | 16:10 ET | [8-K](/filings/0001193125-26-338006.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338006 | | 2026-06-24 | 17:14 ET | [8-K](/filings/0001104659-26-077354.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-077354 | | 2026-06-22 | 08:01 ET | [8-K](/filings/0001104659-26-076091.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-076091 | | 2026-06-12 | 16:30 ET | [8-K](/filings/0001193125-26-269549.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-269549 | | 2026-05-19 | 07:30 ET | [8-K](/filings/0001193125-26-229657.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-229657 | | 2026-05-12 | 08:15 ET | [8-K](/filings/0001193125-26-218251.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-218251 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076742.md), filed Feb 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1813814 - Tickers: DFTX - Exchange: Nasdaq - SIC code: 2833 Medicinal Chemicals & Botanical Products - State of incorporation: A1 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.